|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0017337,
umls-concept:C0024419,
umls-concept:C0028630,
umls-concept:C0030705,
umls-concept:C0086418,
umls-concept:C0087111,
umls-concept:C0092801,
umls-concept:C0185117,
umls-concept:C0205195,
umls-concept:C0205210,
umls-concept:C0392760,
umls-concept:C0393022,
umls-concept:C0596902,
umls-concept:C0855095,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911684,
umls-concept:C2911692
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-2-22
|
|
pubmed:abstractText |
Resistance to nucleoside analogues agents is likely to be multifactorial and could involve a number of mechanisms affecting drug penetration, metabolism and targeting. In vitro studies of resistant human cell lines have confirmed that human concentrative nucleoside transporter 1 (hCNT1)-deficient cells display resistance.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
pubmed-author:AndreolaGG,
pubmed-author:BertoliniFF,
pubmed-author:BilligII,
pubmed-author:CalabreseLL,
pubmed-author:FabbriAA,
pubmed-author:FrigeriFF,
pubmed-author:LaszloDD,
pubmed-author:MartinelliGG,
pubmed-author:RabascioCC,
pubmed-author:RadiceDD,
pubmed-author:RigacciLL,
pubmed-author:SaronniLL
|
|
pubmed:copyrightInfo |
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
454-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19647871-Adult,
pubmed-meshheading:19647871-Aged,
pubmed-meshheading:19647871-Antibodies, Monoclonal,
pubmed-meshheading:19647871-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:19647871-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19647871-Cladribine,
pubmed-meshheading:19647871-Female,
pubmed-meshheading:19647871-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19647871-Humans,
pubmed-meshheading:19647871-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:19647871-Male,
pubmed-meshheading:19647871-Membrane Transport Proteins,
pubmed-meshheading:19647871-Middle Aged,
pubmed-meshheading:19647871-Models, Biological,
pubmed-meshheading:19647871-Prognosis,
pubmed-meshheading:19647871-Treatment Outcome,
pubmed-meshheading:19647871-Tumor Markers, Biological,
pubmed-meshheading:19647871-Waldenstrom Macroglobulinemia
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
|
|
pubmed:affiliation |
Dept of Haematology, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy. cristina.rabascio@ieo.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
